Literature DB >> 18817866

A combination of Lox-1 and Nox1 regulates TLR9-mediated foam cell formation.

Jin-Gu Lee1, Eun-Jung Lim, Dae-Weon Park, Sun-Hye Lee, Jae-Ryong Kim, Suk-Hwan Baek.   

Abstract

The formation of foam cells is the hallmark of early atherosclerotic lesions, and the uptake of modified low-density lipoprotein (LDL) by macrophage scavenger receptors is thought to be a key process in their formation. In this study, we examined the role of lectin-like oxLDL receptor-1 (Lox-1) and NADPH oxidase 1 (Nox1) in toll-like receptor 9 (TLR9)-mediated foam cell formation. TLR9 activation of Raw264.7 cells or mouse primary peritoneal macrophages by CpG ODN treatment enhanced Lox-1 gene and protein expression. In addition, CpG ODN-induced Nox1 mRNA expression, which in turn increased foam cell formation. The inhibition of CpG ODN-induced reactive oxygen species (ROS) generation by treatment with antioxidants, as well as with knockdown of Nox1 using siRNA, suppressed the formation of foam cells. The induction of Lox-1 and Nox1 by CpG ODN was regulated via the TLR9-p38 MAPK signaling pathway. CpG ODN also increased NFkappaB activity, and a potent inhibitor of NFkappaB that significantly blocked CpG-induced Nox1 expression, suggesting that Nox1 regulation is mediated through an NFkappaB-dependent mechanism. Taken together, these results suggest that a combination of Lox-1 and Nox1 plays a key role in the TLR9-mediated formation of foam cells via the p38 MAPK pathway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18817866     DOI: 10.1016/j.cellsig.2008.08.022

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  33 in total

1.  TLR3 and TLR4 as potential clinical biomarkers for in-stent restenosis in drug-eluting stents patients.

Authors:  Shao Liang; Ma Aiqun; Li Jiwu; Zhang Ping
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

Review 2.  Atherosclerosis and the role of immune cells.

Authors:  Fulya Ilhan; Sevgi Tas Kalkanli
Journal:  World J Clin Cases       Date:  2015-04-16       Impact factor: 1.337

Review 3.  Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system.

Authors:  Bernard Lassègue; Alejandra San Martín; Kathy K Griendling
Journal:  Circ Res       Date:  2012-05-11       Impact factor: 17.367

Review 4.  Therapeutic potential of NADPH oxidase 1/4 inhibitors.

Authors:  G Teixeira; C Szyndralewiez; S Molango; S Carnesecchi; F Heitz; P Wiesel; J M Wood
Journal:  Br J Pharmacol       Date:  2016-07-14       Impact factor: 8.739

Review 5.  The Role of Toll-like Receptors in Atherothrombotic Cardiovascular Disease.

Authors:  Ying Zhou; Peter J Little; Liam Downey; Rizwana Afroz; Yuao Wu; Hang T Ta; Suowen Xu; Danielle Kamato
Journal:  ACS Pharmacol Transl Sci       Date:  2020-02-06

Review 6.  Nitroxidative Signaling Mechanisms in Pathological Pain.

Authors:  Peter M Grace; Andrew D Gaudet; Vasiliki Staikopoulos; Steven F Maier; Mark R Hutchinson; Daniela Salvemini; Linda R Watkins
Journal:  Trends Neurosci       Date:  2016-11-12       Impact factor: 13.837

Review 7.  Natural killer T cells and atherosclerosis: form and function meet pathogenesis.

Authors:  Nicole A Braun; Roman Covarrubias; Amy S Major
Journal:  J Innate Immun       Date:  2010-03-17       Impact factor: 7.349

8.  Serum amyloid A stimulates macrophage foam cell formation via lectin-like oxidized low-density lipoprotein receptor 1 upregulation.

Authors:  Ha Young Lee; Sang Doo Kim; Suk-Hwan Baek; Joon Hyuk Choi; Kyung-Hyun Cho; Brian A Zabel; Yoe-Sik Bae
Journal:  Biochem Biophys Res Commun       Date:  2013-02-27       Impact factor: 3.575

Review 9.  Emerging role of Toll-like receptors in atherosclerosis.

Authors:  Linda K Curtiss; Peter S Tobias
Journal:  J Lipid Res       Date:  2008-11-01       Impact factor: 5.922

Review 10.  The expression and functions of toll-like receptors in atherosclerosis.

Authors:  Jennifer E Cole; Ektoras Georgiou; Claudia Monaco
Journal:  Mediators Inflamm       Date:  2010-06-24       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.